Teneo_logo_FINAL_whitebkgnd.png
Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma
July 15, 2019 08:00 ET | TeneoBio, Inc
NEWARK, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting
June 01, 2019 09:00 ET | Bellicum Pharmaceuticals, Inc.
Data provides further evidence that GoCAR-T® technology boosts expansion and persistence of therapeutic T cells in patients T cell expansion and persistence greater in patients who received...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2019 16:14 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
May 29, 2019 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting
May 15, 2019 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019 08:30 ET | Harpoon Therapeutics
Continued enrollment of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerNet proceeds of approximately $71 million from completion...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update
May 07, 2019 07:30 ET | Bellicum Pharmaceuticals, Inc.
Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
April 29, 2019 08:00 ET | TeneoBio, Inc
NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific...
Vineti_vertical@2x.png
Vineti and Marker Therapeutics announce strategic partnership to support diverse cell therapy portfolio
April 22, 2019 10:00 ET | Vineti
SAN FRANCISCO and HOUSTON, April 22, 2019 (GLOBE NEWSWIRE) -- Vineti Inc., the leading software platform of record for personalized therapeutics, today announced a new partnership to advance and...
Harpoon_logo (002).jpg
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers
April 18, 2019 07:30 ET | Harpoon Therapeutics
HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development...